Abcc6 Null Mice-a Model for Mineralization Disorder PXE Shows Vertebral Osteopenia Without Enhanced Intervertebral...

Area of Science:

• Biochemistry
• Orthopedics
• Genetics

Background:

• Chronic low back pain is linked to intervertebral disc degeneration and dystrophic calcification.
• ATP-binding cassette sub-family C member 6 (ABCC6) regulates pyrophosphate (PPi) levels, and its mutations cause pseudoxanthoma elasticum (PXE), a mineralization disorder.
• The role of ABCC6 in spinal mineralization and bone quality is unknown.

Purpose of the Study:

• To investigate the impact of ABCC6 loss-of-function on vertebral bone and intervertebral disc aging in a mouse model.
• To evaluate potassium citrate as a potential therapeutic agent for ABCC6-deficiency-related bone abnormalities.

Main Methods:

• Utilized the Abcc6-/- mouse model of PXE to study age-dependent changes in vertebrae and intervertebral discs.
• Assessed trabecular bone quality, bone resorption (TRAP staining), and bone formation (TNAP staining).
• Administered oral potassium citrate to Abcc6-/- mice to assess its therapeutic effects on bone parameters.

Main Results:

• Abcc6-/- mice showed significantly diminished trabecular bone quality at 7 and 18 months of age compared to wild-type mice.
• Vertebrae of Abcc6-/- mice exhibited increased TRAP and decreased TNAP staining, indicating altered bone remodeling.
• Loss of ABCC6 resulted in a mild aging phenotype in intervertebral discs without dystrophic mineralization.
• Potassium citrate treatment inhibited osteoclastic activity and improved bone mechanical properties in Abcc6-/- mice.

Conclusions:

• Loss of ABCC6 compromises vertebral bone quality and dysregulates osteoblast-osteoclast coupling.
• Ectopic mineralization in the intervertebral disc appears to be tightly regulated, even in the absence of ABCC6.
• Potassium citrate demonstrates therapeutic potential for improving bone quality in conditions associated with ABCC6 deficiency.